JEADVClinical trial
52-week ivarmacitinib in moderate-to-severe atopic dermatitis
A phase 3 trial.
ConclusionIvarmacitinib was associated with generally maintained improvement through Week 52, with a safety profile generally consistent with that observed during the placebo-controlled period. Because the extension phase had no placebo control after Week 16, long-term efficacy findings should be interpreted as descriptive.
Zhao Y, Gooderham M, … senior author Zhang JJournal of the European Academy of Dermatology and Venereology